Option Care Health (OPCH) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic Positioning and Market Overview

• Operates a national platform serving patients in all 50 states, with over 5,000 clinicians and 170+ locations, including 90+ full-service pharmacies.

• In-network with all top 10 payers, offering a diverse portfolio including 50+ limited distribution drugs and no single payer over 15% of revenue.

• Provides high-quality, affordable care in home and alternate sites, with 24/7 clinical support and a comprehensive pharmacy network.

• Limited exposure to direct government reimbursement, focusing on value for health systems, payers, and pharma partners.

• Consistent performance has enabled strong cash flow, balance sheet strength, and ongoing investments in technology, talent, and infrastructure.

Financial Performance and Capital Deployment

• Achieved 13% net revenue CAGR and 19% adjusted EBITDA CAGR since 2020, doubling profit generation over five years.

• Preliminary 2024 net revenue reached $4.99B–$5.0B, a 16% increase year-over-year; adjusted EBITDA was $441M–$444M, up 4% from prior year.

• Over $500 million in share repurchases since mid-2023, with $90 million repurchased in Q4 2024 and a new $500 million authorization approved.

• Reaffirmed at least $300 million in operating cash flow for 2024, with $250 million in free cash flow expected.

• 2025 guidance: net revenue of $5.2B–$5.4B, adjusted EBITDA of $445M–$465M, adjusted EPS of $1.59–$1.69.

Growth Strategy and Portfolio Management

• Signed a definitive agreement to acquire Intramed Plus, expanding presence in South Carolina, expected to close Q1 2025.

• Maintains a balanced portfolio: 25% acute, 75% chronic therapies, with no single therapy (excluding Stelara) over 5% of revenue.

• Over 50% of revenue from branded drugs, but more than 75% of product margin from generics and biosimilars.

• Investments continue in infusion suites, clinics, and pharmacy infrastructure to broaden access and clinical oversight.

• Intends to broaden infusion clinic footprint and deepen partnerships with payers and health systems.